We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Drafts Guidance on NTM-PD Caused by MAC Trials
FDA Drafts Guidance on NTM-PD Caused by MAC Trials
The FDA has laid out its draft recommendations for designs, study populations and endpoints for clinical trials of drugs designed to treat naïve and refractory nontuberculous mycobacterial pulmonary disease (NTM-PD) caused by Mycobacterium avium complex (MAC).